Cingulate NMDA NR2B receptors contribute to morphine-induced analgesic tolerance

Shanelle W Ko, Long-Jun Wu, Fanny Shum, Jessica Quan, Min Zhuo, Shanelle W Ko, Long-Jun Wu, Fanny Shum, Jessica Quan, Min Zhuo

Abstract

Morphine is widely used to treat chronic pain, however its utility is hindered by the development of tolerance to its analgesic effects. While N-methyl-D-aspartate (NMDA) receptors are known to play roles in morphine tolerance and dependence, less is known about the roles of individual NMDA receptor subtypes. In this study, Ro 256981, an antagonist of the NMDA receptor subunit NR2B, was used to reduce the expression of analgesic tolerance to morphine. The mechanisms altered with chronic drug use share similarities with those underlying the establishment of long-tem potentiation (LTP) and behavioral memory. Since NMDA NR2B receptors in the anterior cingulate cortex (ACC) play roles in the establishment of LTP and fear memory, we explored their role in changes that occur in this region after chronic morphine. Both systemic and intra-ACC inhibition of NR2B in morphine-tolerant animals inhibited the expression of analgesic tolerance. Electrophysiological recordings revealed a significant increase in the NR2B component of NMDA receptor mediated excitatory postsynaptic currents (EPSCs), at both synaptic and extra-synaptic sites. However, there was no change in alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor mediated EPSCs. This study suggests that selective inhibition of NMDA NR2B receptors may prove useful in combating the development of analgesic tolerance to morphine and proposes a novel role for the ACC in opioid tolerance and morphine induced changes in synaptic plasticity.

Figures

Figure 1
Figure 1
The role of NR2B receptors in acute morphine-induced analgesia and analgesic tolerance. (A) Morphine analgesia was greater in mice pretreated with Ro25-6981 (5 mg/kg, i.p., n = 5) compared to mice pretreated with saline (n = 4) beginning 90 min after injection. There was a significant effect of treatment (p < 0.05) with significant differences occurring at 90, 120, 150 and 180 minutes after injection (p < 0.05 for all). * represents a significant difference from saline injected mice. (B) Response latencies were significantly increased by Ro 256981 injection (5 mg/kg, i.p., n = 8). Day 7 vs. Day 8, p < 0.001). * represents a significant difference from responses on Day 6 and 7. (C) Daily co-administration of Ro 256981 (5 mg/kg, i.p.) with morphine (10 mg/kg, s.c.) attenuates opioid analgesic tolerance (p < 0.001) compared to mice receiving morphine (n = 7) or saline (n = 5). There was no difference between morphine treated and Ro256981+morphine treated mice on Day 1 (p = 0.74) but a significant difference arose on Day 2 (p < 0.001) and persisted during Days 3, 4, 6 and 7 (p < 0.001, p < 0.01, p < 0.05, p < 0.05 respectively).
Figure 2
Figure 2
Antagonism of NR2B receptors in the ACC can reverse opioid analgesic tolerance compared to mice receiving saline in the ACC. (A) Analgesic tolerance in ACC cannulated mice developed over the seven-day test period. (B) Bilateral microinjection of Ro 256981 (1 μg in 1 μl, bilaterally, n = 7; filled circles) into the ACC significantly increased response latencies compared to mice receiving saline injections (n = 5; open circles) and to responses on Day 7.
Figure 3
Figure 3
No change in mEPSCs in morphine treated mice. (A) Representative traces showing mEPSCs in saline (upper) or morphine treated mice (lower). (B) Pooled data showed that there is no difference in mEPSC frequency in saline (n = 16) and morphine treated groups (n = 16). (C) No difference in amplitude of mEPSCs in the ACC of saline (n = 16) and morphine treated groups (n = 16).
Figure 4
Figure 4
Enhanced NR2B NMDA receptor function in morphine-treated mice. (A) Representative traces showing that the NR2B component was revealed by application of Ro256981 (3 μM) in saline (upper) or morphine treated mice (lower). (B) Pooled data showed a significant increase in the NR2B component in morphine treated mice (n = 8) compared with that of saline group (n = 6). (C) A short train of stimuli (200 Hz, 7 pulses) induced lager NMDA EPSCs. The NR2B component, including extrasynaptic NR2B, was revealed by application of Ro 256981 (3 μM) in saline (upper) or morphine treated mice (lower). (D) Pooled data showed a significant increase in the NR2B component of short train-induced NMDA current in morphine treated mice (n = 7) compared with that of the saline group (n = 7).
Figure 5
Figure 5
Enhanced cingulate LTP in morphine treated mice. (A) LTP was induced with the spike-timing protocol in ACC neurons in wild-type mice (n = 7). (B) Enhanced potentiation was observed in morphine treated mice (n = 8). The insets show averages of six EPSCs at baseline responses (1) and 30 min (2) after LTP induction (arrow). The dashed line indicates the mean basal synaptic response. (C) There was a significant increase in LTP in morphine treated mice compared to saline treated group.

References

    1. Kozela E, Popik P. The effects of NMDA receptor antagonists on acute morphine antinociception in mice. Amino Acids. 2002;23:163–168. doi: 10.1007/s00726-001-0123-5.
    1. Chizh BA, Headley PM, Tzschentke TM. NMDA receptor antagonists as analgesics: focus on the NR2B subtype. Trends Pharmacol Sci. 2001;22:636–642. doi: 10.1016/S0165-6147(00)01863-0.
    1. Trujillo KA. Are NMDA receptors involved in opiate-induced neural and behavioral plasticity? A review of preclinical studies. Psychopharmacology (Berl) 2000;151:121–141. doi: 10.1007/s002130000416.
    1. Bisaga A, Popik P. In search of a new pharmacological treatment for drug and alcohol addiction: N-methyl-D-aspartate (NMDA) antagonists. Drug Alcohol Depend. 2000;59:1–15. doi: 10.1016/S0376-8716(99)00107-6.
    1. Turchan J, Maj M, Przewlocka B. The effect of drugs of abuse on NMDAR1 receptor expression in the rat limbic system. Drug Alcohol Depend. 2003;72:193–196. doi: 10.1016/S0376-8716(03)00193-5.
    1. Nemmani KV, Grisel JE, Stowe JR, Smith-Carliss R, Mogil JS. Modulation of morphine analgesia by site-specific N-methyl-D-aspartate receptor antagonists: dependence on sex, site of antagonism, morphine dose, and time. Pain. 2004;109:274–283. doi: 10.1016/j.pain.2004.01.035.
    1. Nakama-Kitamura M. The N-Methyl-D-aspartate receptor antagonist dizocilpine inhibits associative antinociceptive tolerance to morphine in mice: relation with memory. J Pharmacol Sci. 2005;97:75–82. doi: 10.1254/jphs.FPJ04024X.
    1. Trujillo KA, Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science. 1991;251:85–87. doi: 10.1126/science.1824728.
    1. Manning BH, Mao J, Frenk H, Price DD, Mayer DJ. Continuous co-administration of dextromethorphan or MK-801 with morphine: attenuation of morphine dependence and naloxone-reversible attenuation of morphine tolerance. Pain. 1996;67:79–88. doi: 10.1016/0304-3959(96)81972-5.
    1. Vicini S, Wang JF, Li JH, Zhu WJ, Wang YH, Luo JH, Wolfe BB, Grayson DR. Functional and pharmacological differences between recombinant N-methyl-D-aspartate receptors. J Neurophysiol. 1998;79:555–566.
    1. Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron. 1994;12:529–540. doi: 10.1016/0896-6273(94)90210-0.
    1. Loftis JM, Janowsky A. The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. Pharmacol Ther. 2003;97:55–85. doi: 10.1016/S0163-7258(02)00302-9.
    1. Dumas TC. Developmental regulation of cognitive abilities: modified composition of a molecular switch turns on associative learning. Prog Neurobiol. 2005;76:189–211. doi: 10.1016/j.pneurobio.2005.08.002.
    1. Wiltgen BJ, Brown RA, Talton LE, Silva AJ. New circuits for old memories: the role of the neocortex in consolidation. Neuron. 2004;44:101–108. doi: 10.1016/j.neuron.2004.09.015.
    1. Devinsky O, Morrell MJ, Vogt BA. Contributions of anterior cingulate cortex to behaviour. Brain. 1995;118:279–306. doi: 10.1093/brain/118.1.279.
    1. Zhuo M. Glutamate receptors and persistent pain: targeting forebrain NR2B subunits. Drug Discov Today. 2002;7:259–267. doi: 10.1016/S1359-6446(01)02138-9.
    1. Peoples LL. Neuroscience. Will, anterior cingulate cortex, and addiction. Science. 2002;296:1623–1624. doi: 10.1126/science.1072997.
    1. Tang YP, Shimizu E, Dube GR, Rampon C, Kerchner GA, Zhuo M, Liu G, Tsien JZ. Genetic enhancement of learning and memory in mice. Nature. 1999;401:63–69. doi: 10.1038/43432.
    1. Wei F, Wang GD, Kerchner GA, Kim SJ, Xu HM, Chen ZF, Zhuo M. Genetic enhancement of inflammatory pain by forebrain NR2B overexpression. Nat Neurosci. 2001;4:164–169. doi: 10.1038/83993.
    1. Zhao MG, Toyoda H, Lee YS, Wu LJ, Ko SW, Zhang XH, Jia Y, Shum F, Xu H, Li BM, et al. Roles of NMDA NR2B subtype receptor in prefrontal long-term potentiation and contextual fear memory. Neuron. 2005;47:859–872. doi: 10.1016/j.neuron.2005.08.014.
    1. Wu LJ, Toyoda H, Zhao MG, Lee YS, Tang J, Ko SW, Jia YH, Shum FW, Zerbinatti CV, Bu G, et al. Upregulation of forebrain NMDA NR2B receptors contributes to behavioral sensitization after inflammation. J Neurosci. 2005;25:11107–11116. doi: 10.1523/JNEUROSCI.1678-05.2005.
    1. Hyman SE. Addiction: a disease of learning and memory. Am J Psychiatry. 2005;162:1414–1422. doi: 10.1176/appi.ajp.162.8.1414.
    1. Kelley AE. Memory and addiction: shared neural circuitry and molecular mechanisms. Neuron. 2004;44:161–179. doi: 10.1016/j.neuron.2004.09.016.
    1. Toyoda H, Zhao MG, Zhuo M. Roles of NMDA receptor NR2A and NR2B subtypes for long-term depression in the anterior cingulate cortex. Eur J Neurosci. 2005;22:485–494. doi: 10.1111/j.1460-9568.2005.04236.x.
    1. Lozovaya NA, Grebenyuk SE, Tsintsadze T, Feng B, Monaghan DT, Krishtal OA. Extrasynaptic NR2B and NR2D subunits of NMDA receptors shape 'superslow' afterburst EPSC in rat hippocampus. J Physiol. 2004;558:451–463. doi: 10.1113/jphysiol.2004.063792.
    1. Redwine KE, Trujillo KA. Effects of NMDA receptor antagonists on acute mu-opioid analgesia in the rat. Pharmacol Biochem Behav. 2003;76:361–372. doi: 10.1016/j.pbb.2003.08.009.
    1. Kozela E, Danysz W, Popik P. Uncompetitive NMDA receptor antagonists potentiate morphine antinociception recorded from the tail but not from the hind paw in rats. Eur J Pharmacol. 2001;423:17–26. doi: 10.1016/S0014-2999(01)01084-6.
    1. Craft RM, Lee DA. NMDA antagonist modulation of morphine antinociception in female vs. male rats. Pharmacol Biochem Behav. 2005;80:639–649. doi: 10.1016/j.pbb.2005.02.003.
    1. Bilsky EJ, Inturrisi CE, Sadee W, Hruby VJ, Porreca F. Competitive and non-competitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to selective mu or delta opioid agonists in mice. Pain. 1996;68:229–237. doi: 10.1016/S0304-3959(96)03185-5.
    1. Elliott K, Minami N, Kolesnikov YA, Pasternak GW, Inturrisi CE. The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids. Pain. 1994;56:69–75. doi: 10.1016/0304-3959(94)90151-1.
    1. Suh H, Song D, Huh S, Kim YH. Differential potentiative effects of glutamate receptor antagonists in the production of antinociception induced by opioids administered intrathecally in the mouse. Brain Res Bull. 2000;52:143–150. doi: 10.1016/S0361-9230(00)00250-1.
    1. Lipa SM, Kavaliers M. Sex differences in the inhibitory effects of the NMDA antagonist, MK-801, on morphine and stress-induced analgesia. Brain Res Bull. 1990;24:627–630. doi: 10.1016/0361-9230(90)90169-Z.
    1. Lutfy K, Hurlbut DE, Weber E. Blockade of morphine-induced analgesia and tolerance in mice by MK-801. Brain Res. 1993;616:83–88. doi: 10.1016/0006-8993(93)90195-S.
    1. Bhargava HN. Enhancement of morphine actions in morphine-naive and morphine-tolerant mice by LY 235959 a competitive antagonist of the NMDA receptor. Gen Pharmacol. 1997;28:61–64.
    1. Bulka A, Wiesenfeld-Hallin Z, Xu XJ. Differential antinociception by morphine and methadone in two sub-strains of Sprague-Dawley rats and its potentiation by dextromethorphan. Brain Res. 2002;942:95–100. doi: 10.1016/S0006-8993(02)02701-4.
    1. Plesan A, Hedman U, Xu XJ, Wiesenfeld-Hallin Z. Comparison of ketamine and dextromethorphan in potentiating the antinociceptive effect of morphine in rats. Anesth Analg. 1998;86:825–829. doi: 10.1097/00000539-199804000-00027.
    1. Hoffmann O, Wiesenfeld-Hallin Z. Dextromethorphan potentiates morphine antinociception, but does not reverse tolerance in rats. Neuroreport. 1996;7:838–840. doi: 10.1097/00001756-199602290-00037.
    1. Wong CS, Cherng CH, Luk HN, Ho ST, Tung CS. Effects of NMDA receptor antagonists on inhibition of morphine tolerance in rats: binding at mu-opioid receptors. Eur J Pharmacol. 1996;297:27–33. doi: 10.1016/0014-2999(95)00728-8.
    1. Trujillo KA, Akil H. Inhibition of opiate tolerance by non-competitive N-methyl-D-aspartate receptor antagonists. Brain Res. 1994;633:178–188. doi: 10.1016/0006-8993(94)91538-5.
    1. Tiseo PJ, Cheng J, Pasternak GW, Inturrisi CE. Modulation of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY274614: assessment of opioid receptor changes. J Pharmacol Exp Ther. 1994;268:195–201.
    1. Elliott K, Hynansky A, Inturrisi CE. Dextromethorphan attenuates and reverses analgesic tolerance to morphine. Pain. 1994;59:361–368. doi: 10.1016/0304-3959(94)90022-1.
    1. Allen RM, Dykstra LA. Role of morphine maintenance dose in the development of tolerance and its attenuation by an NMDA receptor antagonist. Psychopharmacology (Berl) 2000;148:59–65. doi: 10.1007/s002130050025.
    1. Bernardi M, Bertolini A, Szczawinska K, Genedani S. Blockade of the polyamine site of NMDA receptors produces antinociception and enhances the effect of morphine, in mice. Eur J Pharmacol. 1996;298:51–55. doi: 10.1016/0014-2999(95)00778-4.
    1. Fischer BD, Carrigan KA, Dykstra LA. Effects of N-methyl-D-aspartate receptor antagonists on acute morphine-induced and l-methadone-induced antinociception in mice. J Pain. 2005;6:425–433. doi: 10.1016/j.jpain.2005.02.003.
    1. Childress AR, Mozley PD, McElgin W, Fitzgerald J, Reivich M, O'Brien CP. Limbic activation during cue-induced cocaine craving. Am J Psychiatry. 1999;156:11–18.
    1. Sell LA, Morris J, Bearn J, Frackowiak RS, Friston KJ, Dolan RJ. Activation of reward circuitry in human opiate addicts. Eur J Neurosci. 1999;11:1042–1048. doi: 10.1046/j.1460-9568.1999.00522.x.
    1. Goldstein RZ, Volkow ND. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry. 2002;159:1642–1652. doi: 10.1176/appi.ajp.159.10.1642.
    1. Breiter HC, Gollub RL, Weisskoff RM, Kennedy DN, Makris N, Berke JD, Goodman JM, Kantor HL, Gastfriend DR, Riorden JP, et al. Acute effects of cocaine on human brain activity and emotion. Neuron. 1997;19:591–611. doi: 10.1016/S0896-6273(00)80374-8.
    1. Kilts CD, Schweitzer JB, Quinn CK, Gross RE, Faber TL, Muhammad F, Ely TD, Hoffman JM, Drexler KP. Neural activity related to drug craving in cocaine addiction. Arch Gen Psychiatry. 2001;58:334–341. doi: 10.1001/archpsyc.58.4.334.
    1. Weissenborn R, Robbins TW, Everitt BJ. Effects of medial prefrontal or anterior cingulate cortex lesions on responding for cocaine under fixed-ratio and second-order schedules of reinforcement in rats. Psychopharmacology (Berl) 1997;134:242–257. doi: 10.1007/s002130050447.
    1. Neisewander JL, Baker DA, Fuchs RA, Tran-Nguyen LT, Palmer A, Marshall JF. Fos protein expression and cocaine-seeking behavior in rats after exposure to a cocaine self-administration environment. J Neurosci. 2000;20:798–805.
    1. Schroeder BE, Holahan MR, Landry CF, Kelley AE. Morphine-associated environmental cues elicit conditioned gene expression. Synapse. 2000;37:146–158. doi: 10.1002/1098-2396(200008)37:2<146::AID-SYN8>;2-#.
    1. Harris GC, Aston-Jones G. Enhanced morphine preference following prolonged abstinence: association with increased Fos expression in the extended amygdala. Neuropsychopharmacology. 2003;28:292–299. doi: 10.1038/sj.npp.1300037.
    1. Vogt LJ, Sim-Selley LJ, Childers SR, Wiley RG, Vogt BA. Colocalization of mu-opioid receptors and activated G-proteins in rat cingulate cortex. J Pharmacol Exp Ther. 2001;299:840–848.
    1. LaGraize SC, Borzan J, Peng YB, Fuchs PN. Selective regulation of pain affect following activation of the opioid anterior cingulate cortex system. Exp Neurol. 2006;197:22–30.
    1. Hao Y, Yang JY, Guo M, Wu CF, Wu MF. Morphine decreases extracellular levels of glutamate in the anterior cingulate cortex: an in vivo microdialysis study in freely moving rats. Brain Res. 2005;1040:191–196. doi: 10.1016/j.brainres.2005.01.072.
    1. Zhao M, Joo DT. Subpopulation of dorsal horn neurons displays enhanced N-methyl-D-aspartate receptor function after chronic morphine exposure. Anesthesiology. 2006;104:815–825. doi: 10.1097/00000542-200604000-00028.
    1. Zhuo M. Cortical excitation and chronic pain. Trends Neurosci. 2008;31:199–207. doi: 10.1016/j.tins.2008.01.003.
    1. Ko S, Zhao MG, Toyoda H, Qiu CS, Zhuo M. Altered behavioral responses to noxious stimuli and fear in glutamate receptor 5 (GluR5)- or GluR6-deficient mice. J Neurosci. 2005;25:977–984. doi: 10.1523/JNEUROSCI.4059-04.2005.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren